InMed Provides Update on Progress of Its Development Program for Epidermolysis Bullosa
VANCOUVER, BRITISH COLUMBIA–(Marketwired – Nov. 4, 2015) – InMed Pharmaceuticals Inc. (“InMed”) (CSE:IN)(OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies would like to provide an update on the progress of INM-750, its lead product in development for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder.
INM-750 is a topical formulation of phytocannabinoids that have been carefully selected using our proprietary bioinformatics discovery platform to treat: (i) the underlying cause of the disease in patients with epidermolysis bullosa simplex (the most common form of the disease), and (ii) to treat the major symptoms of the disease in all patients with EB.
InMed’s initial pre-clinical studies were focused on studying the potential of INM-750 to treat the cause of the disease by modulating the expression of the various keratins that are critical to maintaining the integrity of the skin. We have previously reported that InMed has been able to demonstrate that certain phytocannabinoids are able to positively influence the expression of the key keratins K5, K6, K14, K15 and K16. We continue to make progress in studying the effect of different cannabinoids at different doses on keratin expression, and a summary of our initial results are now available on our website.
InMed is now pleased to report that INM-750 has demonstrated positive effects in pre-clinical studies on wound healing and in inflammation. InMed has been studying the potential of certain cannabinoids to expedite the wound healing process using the electric cell-substrate impedance sensing (ECIS) wounding assay. The ECIS wounding assay is a state-of-the-art assay that replaces the traditional scrape or scratch assay. Using this assay, InMed has been able to identify certain cannabinoids that significantly potentiate the wound healing process, when compared to other less active cannabinoids, or to the vehicle control. Dr. Sazzad Hossain, Chief Scientific Officer of InMed, stated, “The results we are obtaining with the ECIS wound assay are significant for the development of INM-750. Through the use of the ECIS assay we are able to demonstrate the wound healing and skin regeneration properties of INM-750; these properties will be critical to help alleviate the primary symptoms of patients with EB”.
In addition to the ECIS studies, InMed has also studied the anti-inflammatory effect of certain cannabinoids included in INM-750. It has been demonstrated that cannabinoids included in INM-750 are able to down regulate the production of IL-8 by human keratinocytes, and inhibit IFNɣ/TNF⍺ induced production of IL-6 by human keratinocytes. Dr. Sazzad states, “These results are important to demonstrate that in addition to having an effect on wound healing, the cannabinoids included in INM-750 should also help down regulate the chronic inflammation that is present in EB patients”.
InMed continues to develop INM-750 with the goal of entering the clinic in the first half of 2016. Initial proof of concept studies in human subjects should be completed by the end of 2016. Paul Brennan, CEO of InMed says “I am pleased with the progress of our development program, and the data that has been generated by Dr. Hossain and his colleagues. INM-750 has the potential to provide a significant addition to the treatment options for patients with EB and EBS.”
A summary of the pre-clinical results on INM-750 is available on InMed’s website under the Investors and the Pipeline sections.
About Epidermolysis bullosa simplex (EBS)
Epidermolysis bullosa simplex (EBS) is one of the major forms of epidermolysis bullosa (EB), a group of genetic conditions that cause the skin to be very fragile and to blister easily. It is a result of a defect in anchoring between the epidermis and the dermis, resulting in friction and skin fragility. The severity of this condition ranges from mild to lethal. There is no cure or approved treatments for EB. Wound care, pain management and preventative bandaging are currently the only options available.
About InMed
InMed is a preclinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the pharmacology of cannabinoids combined with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com.
Forward Looking Statements
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Investors
Paul Brennan
President and Chief Executive Officer
604.669.7207
paul@inmedpharma.com
Chris Bogart
SVP, Corporate Strategy and Investor Relations
604.669.7207
chris@inmedpharma.com
- Published in News Home
Mobi724 (MOS:CSE) Signs a Commercial Agreement With Movistar
MOBI724 Global Solutions Inc. (MOS:CSE), Signs a Commercial Agreement With Movistar to Provide its Coupon Solution to Movistar’s 17 M Subscribers
Mobi724 Global Solutions Inc. (“Mobi724” or the “Company”) (MOS:CSE), a technology leader in the digital incentives, couponing and payment space, announces that its wholly owned Argentinian subsidiary, Mobi724 S.R.L., has signed a commercial agreement with Movistar to design, implement, integrate, manage and support MOBI724’s mobile coupons solution for Movistar’s Discount and Rewards program.
MOBI724’s innovative global mobile couponing solution will allow Movistar to create, manage and send mobile campaigns to their 17 million subscribers, who will be able to redeem the couponing benefits directly at any point of sale operated by a participating retailer enrolled by MOBI724.
Marcel Vienneau, CEO of the Company, stated: “We are thrilled to team up with such a global leader and offer the best of breed mobile couponing solution for Movistar’s benefits program, a major communication platform, for their 17 million customers. This level of confidence confirms that our approach in developing innovative value added solutions in a very competitive market is gaining momentum.”
About Movistar
Movistar is the major Spanish mobile phone operator owned by Telefónica S.A. It operates in Spain and in most Latin American countries (including Argentina, Brazil, Chile, Uruguay, Peru, Ecuador, Venezuela, Colombia, Mexico, Guatemala, Panamá, El Salvador, Costa Rica and Nicaragua). Movistar is the largest carrier in Spain with 22 million customers (cellphone services only) and 41.58{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of market share. In Latin America, Movistar has a 30{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} market share with almost 200 million subscribers. In Argentina, Movistar has a 35{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} market share with a base of 17 million subscribers.
About Mobi724 Global Solutions
Mobi724 Global Solutions (CSE:MOS), a corporation based in Montreal, Canada, is a technology leader in digital incentives and payment solutions. It offers a unique and fully integrated suite of solutions – PAYMENT-COUPONING AND LOYALTY all in one.
Our vision is to enhance the value of commoditized payment transactions to the players in this eco-system (ex: customers, banks, mobile carriers and retailers) by adding layers of intelligence to these transactions (i.e. smart transactions) in a seamless manner.
Mobi724 Global Solutions unleashes the true potential of both payment and couponing/rewards transactions for both online and offline points of sale.
The Corporation is fully dedicated to delivering unique “real time” and seamless digital promotional incentives (coupons including card linked coupons, bank cards, loyalty rewards) embedded into the most secured payment environment. The Corporation provides its customers with full and comprehensive traceability and enriched consumer data through its offering. Its solutions enable retailers, manufacturers, offer providers, mobile operators and card issuers to create, manage, deliver and “track and measure” incentive campaigns worldwide to ANY mobile device and allow its redemption at ANY point of sales.
Their credit and debit EMV payment solutions will allow banks to process end to end EMV transactions, focusing on authentication, approved security and quick merchant adoption which allows the users to process payments with a wide range of devices over a secure and seamless transaction.
Mobi724’s PCI and EMV cloud-based switch, with their device agnostic connectivity, simplifies deployment and integration, and introduces new payment and digital incentives solutions to the market enabling multi layered intelligent transactions therefore SMART TRANSACTIONS.
For more information on its products and on Mobi724 Global Solutions, visit www.mobi724globalsolutions.com.
InMed Provides Update on Progress of its Development Program for Epidermolysis Bullosa
Vancouver, BC – November 04, 2015 – InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies would like to provide an update on the progress of INM-750, its lead product in development for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder.
INM-750 is a topical formulation of phytocannabinoids that have been carefully selected using our proprietary bioinformatics discovery platform to treat: (i) the underlying cause of the disease in patients with epidermolysis bullosa simplex (the most common form of the disease), and (ii) to treat the major symptoms of the disease in all patients with EB.
InMed’s initial pre-clinical studies were focused on studying the potential of INM-750 to treat the cause of the disease by modulating the expression of the various keratins that are critical to maintaining the integrity of the skin. We have previously reported that InMed has been able to demonstrate that certain phytocannabinoids are able to positively influence the expression of the key keratins K5, K6, K14, K15 and K16. We continue to make progress in studying the effect of different cannabinoids at different doses on keratin expression, and a summary of our initial results are now available on our website.
InMed is now pleased to report that INM-750 has demonstrated positive effects in pre-clinical studies on wound healing and in inflammation. InMed has been studying the potential of certain cannabinoids to expedite the wound healing process using the electric cell-substrate impedance sensing (ECIS) wounding assay. The ECIS wounding assay is a state-of-the-art assay that replaces the traditional scrape or scratch assay. Using this assay, InMed has been able to identify certain cannabinoids that significantly potentiate the wound healing process, when compared to other less active cannabinoids, or to the vehicle control. Dr. Sazzad Hossain, Chief Scientific Officer of InMed, stated, “The results we are obtaining with the ECIS wound assay are significant for the development of INM-750. Through the use of the ECIS assay we are able to demonstrate the wound healing and skin regeneration properties of INM-750; these properties will be critical to help alleviate the primary symptoms of patients with EB”.
In addition to the ECIS studies, InMed has also studied the anti-inflammatory effect of certain cannabinoids included in INM-750. It has been demonstrated that cannabinoids included in INM-750 are able to down regulate the production of IL-8 by human keratinocytes, and inhibit IFNɣ/TNF⍺ induced production of IL-6 by human keratinocytes. Dr. Sazzad states, “These results are important to demonstrate that in addition to having an effect on wound healing, the cannabinoids included in INM-750 should also help down regulate the chronic inflammation that is present in EB patients”.
InMed continues to develop INM-750 with the goal of entering the clinic in the first half of 2016. Initial proof of concept studies in human subjects should be completed by the end of 2016. Paul Brennan, CEO of InMed says “I am pleased with the progress of our development program, and the data that has been generated by Dr. Hossain and his colleagues. INM-750 has the potential to provide a significant addition to the treatment options for patients with EB and EBS.”
A summary of the pre-clinical results on INM-750 is available on InMed’s website under the Investors and the Pipeline sections.
About Epidermolysis bullosa simplex (EBS)
Epidermolysis bullosa simplex (EBS) is one of the major forms of epidermolysis bullosa (EB), a group of genetic conditions that cause the skin to be very fragile and to blister easily. It is a result of a defect in anchoring between the epidermis and the dermis, resulting in friction and skin fragility. The severity of this condition ranges from mild to lethal. There is no cure or approved treatments for EB. Wound care, pain management and preventative bandaging are currently the only options available.
About InMed
InMed is a preclinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the pharmacology of cannabinoids combined with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com.
CONTACT: Investors
Paul Brennan
President and Chief Executive Officer
Tel: 604.669.7207
Email: paul@inmedpharma.com
or
Chris Bogart
SVP, Corporate Strategy and Investor Relations
Tel: 604.669.7207
Email: chris@inmedpharma.com
Forward Looking Statements
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
- Published in InMed Pharmaceuticals
InMed’s (IN:CSE) INM-750 Shows Positive Effects on Wound Healing
InMed Provides Update on Progress of Its Development Program for Epidermolysis Bullosa
Including New Pre-clinical Results on the Wound Healing and Anti-inflammatory Properties of INM-750
InMed Pharmaceuticals Inc. (“InMed”) (IN:CSE)(IMLFF:OTCQB), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies would like to provide an update on the progress of INM-750, its lead product in development for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder.
INM-750 is a topical formulation of phytocannabinoids that have been carefully selected using our proprietary bioinformatics discovery platform to treat: (i) the underlying cause of the disease in patients with epidermolysis bullosa simplex (the most common form of the disease), and (ii) to treat the major symptoms of the disease in all patients with EB.
InMed’s initial pre-clinical studies were focused on studying the potential of INM-750 to treat the cause of the disease by modulating the expression of the various keratins that are critical to maintaining the integrity of the skin. We have previously reported that InMed has been able to demonstrate that certain phytocannabinoids are able to positively influence the expression of the key keratins K5, K6, K14, K15 and K16. We continue to make progress in studying the effect of different cannabinoids at different doses on keratin expression, and a summary of our initial results are now available on our website.
InMed is now pleased to report that INM-750 has demonstrated positive effects in pre-clinical studies on wound healing and in inflammation. InMed has been studying the potential of certain cannabinoids to expedite the wound healing process using the electric cell-substrate impedance sensing (ECIS) wounding assay. The ECIS wounding assay is a state-of-the-art assay that replaces the traditional scrape or scratch assay. Using this assay, InMed has been able to identify certain cannabinoids that significantly potentiate the wound healing process, when compared to other less active cannabinoids, or to the vehicle control. Dr. Sazzad Hossain, Chief Scientific Officer of InMed, stated, “The results we are obtaining with the ECIS wound assay are significant for the development of INM-750. Through the use of the ECIS assay we are able to demonstrate the wound healing and skin regeneration properties of INM-750; these properties will be critical to help alleviate the primary symptoms of patients with EB”.
In addition to the ECIS studies, InMed has also studied the anti-inflammatory effect of certain cannabinoids included in INM-750. It has been demonstrated that cannabinoids included in INM-750 are able to down regulate the production of IL-8 by human keratinocytes, and inhibit IFN╔ú/TNFΓì║ induced production of IL-6 by human keratinocytes. Dr. Sazzad states, “These results are important to demonstrate that in addition to having an effect on wound healing, the cannabinoids included in INM-750 should also help down regulate the chronic inflammation that is present in EB patients”.
InMed continues to develop INM-750 with the goal of entering the clinic in the first half of 2016. Initial proof of concept studies in human subjects should be completed by the end of 2016. Paul Brennan, CEO of InMed says “I am pleased with the progress of our development program, and the data that has been generated by Dr. Hossain and his colleagues. INM-750 has the potential to provide a significant addition to the treatment options for patients with EB and EBS.”
A summary of the pre-clinical results on INM-750 is available on InMed’s website under the Investors and the Pipeline sections.
About Epidermolysis bullosa simplex (EBS)
Epidermolysis bullosa simplex (EBS) is one of the major forms of epidermolysis bullosa (EB), a group of genetic conditions that cause the skin to be very fragile and to blister easily. It is a result of a defect in anchoring between the epidermis and the dermis, resulting in friction and skin fragility. The severity of this condition ranges from mild to lethal. There is no cure or approved treatments for EB. Wound care, pain management and preventative bandaging are currently the only options available.
About InMed
InMed is a preclinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the pharmacology of cannabinoids combined with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com.
- Published in Blog, Business, Medical Marijuana
Sirona Biochem Retains Strategic Advisor to Commercialize Glycoproteins
VANCOUVER, BC–(Marketwired – November 03, 2015) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the “Company“) is pleased to announce that it has retained Dr. Mason Ross as a strategic advisor to the Company. Mason’s role will be primarily to provide strategic advice and an action plan for the Company’s glycoprotein project, more specifically, revenue generating opportunities, commercial viability, risks and data gaps.
Mason has extensive experience in the pharmaceutical and biotech fields. He has held various medical and commercial responsibilities at Amgen, including leading the commercialization of their new products, and at GlaxoSmithKline leading medical affairs for their specialty care portfolio. Most recently, Mason was the Vice President of Medical Affairs at Nordion, where he focused on the development and commercialization of TheraSphere®, which was sold to BTG for $200 million.
Mason earned his Honors Bachelor of Science in Physiology (1997), Doctor of Medicine (2001) and Master of Business Administration (2010) from the University of Western Ontario.
“I look forward to working closely with management on the glycoprotein project over the next few months,” said Dr. Mason Ross. “I can’t think of a company that is better positioned than Sirona to demonstrate how novel carbohydrate technology may result in a wide range of useful products. The potential for this technology may be enormous.”
“We decided to bring Mason on board for his proven biotech/pharma successes and to support us in building a plan to commercialize our glycoproteins while we direct our immediate efforts towards closing a major transaction for our newest skin-lightener,” said Dr. Howard Verrico, CEO of Sirona Biochem.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in News Home
Sirona Biochem Retains Strategic Advisor to Commercialize Glycoproteins
Vancouver, British Columbia – November 3, 2015 – Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt/Xetra®: ZSB), (the “Company”) is pleased to announce that it has retained Dr. Mason Ross as a strategic advisor to the Company. Mason’s role will be primarily to provide strategic advice and an action plan for the Company’s glycoprotein project, more specifically, revenue generating opportunities, commercial viability, risks and data gaps.
Mason has extensive experience in the pharmaceutical and biotech fields. He has held various medical and commercial responsibilities at Amgen, including leading the commercialization of their new products, and at GlaxoSmithKline leading medical affairs for their specialty care portfolio. Most recently, Mason was the Vice President of Medical Affairs at Nordion, where he focused on the development and commercialization of TheraSphere®, which was sold to BTG for $200 million.
Mason earned his Honors Bachelor of Science in Physiology (1997), Doctor of Medicine (2001) and Master of Business Administration (2010) from the University of Western Ontario.
“I look forward to working closely with management on the glycoprotein project over the next few months,” said Dr. Mason Ross. “I can’t think of a company that is better positioned than Sirona to demonstrate how novel carbohydrate technology may result in a wide range of useful products. The potential for this technology may be enormous.”
“We decided to bring Mason on board for his proven biotech/pharma successes and to support us in building a plan to commercialize our glycoproteins while we direct our immediate efforts towards closing a major transaction for our newest skin-lightener,” said Dr. Howard Verrico, CEO of Sirona Biochem.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Published in Sirona Biochem
InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$1,000,000
Vancouver, BC — November 2, 2015 – InMed Pharmaceuticals, Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), is pleased to announce that it will conduct a non-brokered private placement of up to 6,666,667 units (“Units”) at a price of $0.15 per Unit for aggregate gross proceeds of up to C$1,000,000. Each Unit will consist of one common share and one of one non-transferable share purchase warrant. Each whole warrant will be exercisable by the holder to acquire one additional common share at a price of $0.30 for a period of twelve (12) months following the closing of the financing.
Completion of the private placement is subject to receipt of regulatory approval. All securities issued will be subject to a statutory four month hold period under applicable Securities Laws.
The net proceeds from this private placement will be used for general working capital purposes. Finders’ fees in cash or warrants may be payable in accordance with the policies of the Exchange.
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com
ON BEHALF OF THE BOARD
InMed Pharmaceuticals Inc.
Paul Brennan
President and Chief Executive Officer
T: 604.669.7207
F: 604.683.2506
E: info@inmedpharma.com
Forward Looking Statements
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
- Published in InMed Pharmaceuticals
InvestmentPitch Media Invites Investors to the TakeStock Alberta Investor Forum in Calgary on November 6th, 2015 – Video Hosted on InvestmentPitch.com
Vancouver, British Columbia–(Newsfile Corp. – October 30, 2015) – InvestmentPitch Media would like to invite investors to the TakeStock Alberta Investor Forum in Calgary on November 6th, to be held at the downtown Ramada Inn, 708 – 8th Avenue SW, from 10:00 am to 6:00 pm.
The full day event will include an exciting lineup of public and private companies across a wide range of industries.
For more details, please watch this video (click here). If this link is not enabled, please visit www.InvestmentPitch.comand enter “TakeStock” in the search box.
If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_nhdm5rag/TakeStock-Alberta-Investor-Forum-in-Calgary–November-6th-2015
Feature speaker, Bruce Edgelow, VP Strategic Initiatives with ATB Corporate Financial Services, will appropriately discuss the energy market in his presentation entitled: “Energy Market Update – What a difference a Year Makes“.
Come meet senior company management from some of Alberta’s most attractive growth stocks across a wide range of industries, including the following:
Aurora Cannabis (CSE: ACB) (www.auroramj.com) – Aurora is a culture and community minded marijuana company that in February 2015 received a license to produce from Health Canada.
eQube Gaming, (TSXV: EQG) (www.eqube.com) – eQube is a leading provider of community and charitable gaming solutions for charitable and commercial gaming facilities. eQube has a majority market share of the Canadian regulated eBingo market, is the leading provider to the Irish digital bingo market and now operates the largest linked bingo game in Western Canada.
Foran Mining Corporation, (TSXV: FOM) (www.foranmining.com) – Foran a copper-zinc exploration and development company focused on the Hanson Lake Camp in east-central Saskatchewan, Canada.
Marapharm Ventures, (CSE: MDM) (www.marapharm.com) – Marapharm invests in emerging markets in the medical and recreational marijuana industry. The business model is to apply for and purchase licenses and facilities in strategic locations.
North Arrow Minerals, (TSXV: NAR) (www.northarrowminerals.com) – North Arrow is a Canadian based exploration company focused on the identification and evaluation of diamond exploration opportunities in Canada.
For more information or to register for this free event, please visit www.takestockab.com.
About InvestmentPitch Media
InvestmentPitch Media is arguably the largest producer and distributer of video content, primarily for small and mid-cap companies. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.
CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com
- Published in Aurora Cannabis
Affinor Growers Closes Financing & Announces Director Resignation
Vancouver (Canada), October 30, 2015 – Affinor Growers (CSE:AFI, OTC:RSSFF, Frankfurt:1AF) (“Affinor” or the “Corporation), a diversified agriculture and biotechnology company with proprietary vertical farming systems, announces that the financing reported on October 27, 2015 has been closed. Mr. Gary Lloyd has also resigned from the Board of Directors to pursue his other businesses but will remain as an advisor to Affinor.
Affinor issued 8,333,333 units (a “Unit”) at $0.06 per Unit, for gross proceeds of $500,000. Each Unit is comprised of one common share and one non-transferable common share purchase warrant. Each warrant entitles the holder to purchase one additional common share for a 24-month period, expiring October 30, 2017, at a price of $0.15 per common share. Affinor now has 99,848,361 common shares outstanding.
As part of the financing, Affinor paid a $50,000 finder’s fee in cash and issued Finder’s warrants, entitling the holders to purchase up to 833,333 common shares for a period of 24 months at $0.15 per share. The securities issued are subject to a four-month hold period, expiring on March 1, 2016.
SBSK Investments Corp. (“SBSK”) of Burnaby, BC was the sole subscriber, resulting in SBSKacquiringapproximately 8.35{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} (basic) and 15.41{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} (partially diluted, assuming the exercise of only SBSK’s warrants) of the issued and outstanding common shares of the Corporation.
SBSK acquired the common shares pursuant to the private placement for investment purposes and has no present intention to acquire further ownership of, or control over, additional securities of the Corporation, but may choose to acquire additional securities of the Corporation in the future for investment purposes.
This news release is being issued pursuant to Part 3 of National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues of the Canadian Securities Administrators. A copy of the report filed by SBSK in connection with the acquisition of the Units is available on the Corporation’s SEDAR profile.
Director Resignation
The Corporation also announces that Mr. Lloyd has resigned from the Board of Directors and will join Affinor’s advisory board.Mr. Lloyd has been helpful in advising Affinor in several areas, specifically regarding the distribution of produce in North America. Affinor wishes to acknowledge and thank Mr. Lloyd for his contributions to the Corporation over the last several months.
About Affinor Growers Inc.
Affinor Growers is a diversified publicly traded company on the Canadian Securities Exchange under the symbol (“AFI”). Affinor is focused on growing high quality crops such as romaine lettuce, spinach and strawberries. Affinor is committed to becoming a pre-eminent grower, using exclusive vertical farming techniques.
On Behalf of the Board of Directors
AFFINOR GROWERS INC.
“Jarrett Malnarick”
President & CEO
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracyof this release.
This press release is not for distribution or dissemination in the United States and accordingly, shall not constitute an offer of securities in the United States. The securities that may be issued pursuant to this press release are not currently qualified by prospectus or registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or the laws of any state, and may not be offered or sold in the United States, or to, or for the account or benefit of United States persons (as defined in Regulation S under the Securities Act) or persons in the United States absent registration or an applicable exemption from the registration requirements. The securities are subject to resale restrictions under applicable securities laws.
FORWARD LOOKING INFORMATION
This News Release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This News Release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995
- Published in Affinor Growers
CSE New Listing – International Wastewater Systems Commences Trading on the Canadian Securities Exchange – Video News Alert on InvestmentPitch.com
Vancouver, British Columbia–(Newsfile Corp. – October 30, 2015) – Following a reverse takeover, International Wastewater Systems (CSE: IWS), formerly Amana Copper, began trading on the Canadian Securities Exchange under the symbol IWS. The company has developed and deployed a patent pending method for extracting heat from wastewater flows.
InvestmentPitch.com has produced a “video news alert“which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter “Wastewater”in the search box.
If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_2q2q5ylj/International-Wastewater-Systems-CSE-IWS-New-Listing
The company’s two proprietary products, the SHARC and PIRANHA wastewater heat exchange systems provide simple and direct heat exchange from untreated waste water, resulting in the most energy-saving, cost-effective and environmentally friendly solutions for heating, cooling and hot water for any building, residential or commercial.
The proprietary filtration unit is the cornerstone of the equipment, separating solids and liquids, the latter of which are sent through a heat exchange process before meeting back up with the solids and exiting back into the main sewer system. Up to 95{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of waste water can be put through this process by simply “plugging in”to existing piping infrastructure.
The systems work together with established heat pump technology to capture and recycle heat that would have otherwise been wasted down the drain. The company’s systems can handle a wide spectrum of applications, including condominiums, hospitals, and office buildings, with the scope extending to energy districts and supplemental use on large geothermal installations. SHARC and PIRANHA systems are custom tailored to building specifications and can be installed as new or retrofit applications.
The shares are trading at $0.60, and with 80.9 million shares outstanding, the company is capitalized at $48.6 million.
For more information, please visit the company’s website www.sewageheatrecovery.com or contact Lynn Mueller, CEO, at 604-475-7710 or email lynnm@iwhes.com.
About InvestmentPitch
InvestmentPitch Media is arguably the largest producer and distributer of video content, primarily for small and mid-cap companies. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.
CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com
- Published in International Wastewater Systems